New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
17:25 EDTSLXP, SLXPSalix to host conference call
Conference call to discuss merger with Cosmo Technologies to form Salix Pharmaceuticals, plc will be held on July 9 at 6 pm. Webcast Link
News For SLXP From The Last 14 Days
Check below for free stories on SLXP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent SLXP news | >>
September 23, 2014
09:17 EDTSLXPSalix, Allergan just started talks over price, CNBC reports
Subscribe for More Information
09:13 EDTSLXPOn The Fly: Pre-market Movers
Subscribe for More Information
08:38 EDTSLXPPershing threatens suit against Allergan if no vote held on Salix deal, WSJ says
Subscribe for More Information
08:31 EDTSLXPSalix takeout price could be $200 per share, says Leerink
Leerink estimates a takeout valuation for Salix (SLXP) of $200 per share, but says it would start recommending investors take profits above $185. The firm believes a potential deal with Allergan (AGN) would likely include an above-average break-up fee. Leerink thinks a competitive bid could surface, and points out Actavis (ACT) has more overlapping cost structure with Salix than Allergan. Shares of Salix are up 9% to $173.48 in pre-market trading after Wall Street Journal reported the company is in merger talks with Allergan.
07:07 EDTSLXPSalix price target raised to $181 from $154 at Cantor
Subscribe for More Information
06:28 EDTSLXPTreasury rules may put Mylan deal at risk, says BMO Capital
BMO Capital believes Treasury's new inversion rules may put the tax benefits of Mylan's (MYL) planned acquisition of Abbott's (ABT) established products business at risk. BMO also thinks the rules impact Salix's (SLXP) pending deal for Cosmo Pharmaceuticals, which it feels may help make a deal with Allergan (AGN) more likely.
September 22, 2014
19:08 EDTSLXPSalix up nearly 10% after hours following WSJ report of possible takeover
Subscribe for More Information
19:03 EDTSLXPAllergan rejected buyout bid from Actavis, in advanced talks for Salix, WSJ says
Subscribe for More Information
08:09 EDTSLXPPar Pharmaceutical in settlement deal with Salix
Subscribe for More Information
September 19, 2014
07:54 EDTSLXPSalix price target raised to $192 from $161 at Canaccord
Subscribe for More Information
September 18, 2014
13:44 EDTSLXPSalix announces FDA sNDA resubmission for XIFAXAN complete
Subscribe for More Information
07:31 EDTSLXPSalix secures additional intellectual property relating to Rifaximin
Salix Pharmaceuticals announced that Cipla granted Salix exclusive rights under certain patent applications in the “Rifaximin Complexes” patent family controlled by Cipla. The grant is on a worldwide basis, excluding the countries of Asia and Africa. Additionally, Salix and Cipla have expanded the scope of their 2009 exclusive license agreement whereby Cipla granted Salix exclusive rights in the U.S., Canada and Mexico under certain patent rights covering amorphous rifaximin. By means of this amendment to the 2009 agreement, the rights already licensed to Salix in the U.S., Canada and Mexico are expanded to include certain patent rights in the European Union, Japan, Australia, New Zealand and South Korea. Salix is required to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement regarding the “Rifaximin Complexes” patent rights. Salix also will pay royalties on net sales of products covered by the “Rifaximin Complexes” patents licensed to Salix
September 17, 2014
08:02 EDTSLXPSalix M&A chatter warranted, says Canaccord
Subscribe for More Information
September 15, 2014
17:32 EDTSLXPSalix announces tentative FDA approval of UCERIS rectal foam
Subscribe for More Information
15:55 EDTSLXPSalix price target raised to $172 from $163 at Buckingham
Subscribe for More Information
15:41 EDTSLXPSalix calls active on takeover chatter
Subscribe for More Information
07:47 EDTSLXPFDA PDUFA Date for Salix Pharmaceuticals Budesonide is September 15, 2014
September 12, 2014
10:00 EDTSLXPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:06 EDTSLXPFollow-up: Salix initiated with an Underperform at Credit Suisse
Subscribe for More Information
06:41 EDTSLXPSalix initiated with an Underperform at Credit Suisse
Subscribe for More Information
1 | 2 | all recent SLXP news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use